Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office.
This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules with similar chemical structures. Specifically, the patent covers methods for treating diseases such as asthma, cancer (including breast and bladder cancer), inflammatory bowel disease, diabetic retinopathy, and other conditions for which antagonism of the adenosine 2B receptor (“A2BR”) offers therapeutic potential.
“This patent provides further protection for our lead molecule, ADO-5030, and our pipeline of best-in-class compounds in the areas of asthma, cancer and other disease indications,” said William Stilley, CEO of Adovate. “It demonstrates Adovate’s leadership in the A2BR space and fortifies Adovate’s dominance in an area of adenosine chemistry we believe is strategic for developing A2BR blockers. It also adds to our patent portfolio, which has patents issuing world-wide.”
Read more here.